Last reviewed · How we verify
NCT06696833
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
EARLY_PHASE1 trial testing QH10304-BAL-01 in B-Cell Acute Lymphoblastic Leukemia, Adult in 18 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 December 2024 |
| Primary completion | 1 December 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- QH10304-BAL-01 — full drug profile →
- Fludarabine (FLUDARABINE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
Conditions studied
- B-Cell Acute Lymphoblastic Leukemia, Adult — all drugs for B-Cell Acute Lymphoblastic Leukemia, Adult →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
14 and older, any sex, with B-Cell Acute Lymphoblastic Leukemia, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-γδT Cell in treating CD19-positive relapsed/refractory B-ALL
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Diverse Subsets of γδT Cells and Their Specific Functions Across Liver Diseases.
Zhan C, Peng C, Wei H, Wei K, et al · · 2025 · cited 4× · PMID 40141420 · DOI 10.3390/ijms26062778 -
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT06696833
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-Cell Acute Lymphoblastic Leukemia, Adult
Currently open trials in the same condition.
- NCT07199855 — Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymph · Phase 2 · active not recruiting
- NCT04214886 — CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies · Phase 1 · active not recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06696833 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 20 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06696833.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing